Vertical Peak Holdings Inc.

OTCPK:SPLI.F Stock Report

Market Cap: US$342.0k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Vertical Peak Holdings Past Earnings Performance

Past criteria checks 0/6

Vertical Peak Holdings has been growing earnings at an average annual rate of 2.9%, while the Pharmaceuticals industry saw earnings growing at 6% annually. Revenues have been declining at an average rate of 24.3% per year.

Key information

2.9%

Earnings growth rate

34.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-24.3%
Return on equityn/a
Net Margin-180.3%
Last Earnings Update30 Apr 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Vertical Peak Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SPLI.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Apr 238-1590
31 Jan 237-1980
31 Oct 227-19100
31 Jul 226-1990
30 Apr 225170
31 Jan 223-170
31 Oct 211-1250
31 Jul 210-1250
30 Apr 21-11-22-10
31 Jan 21-10-17-10
31 Oct 20-7-930
31 Jul 200-1160
30 Apr 2017-23160
31 Jan 2022-30190
31 Oct 1925-32200
31 Jul 1924-28200
30 Apr 1921-19170
31 Jan 1918-12140
31 Oct 1811-790
31 Jul 186-1060
30 Apr 183-940
31 Jan 180-840
31 Oct 171-730
31 Jul 171-540
30 Apr 171-330
31 Jan 171-220
31 Oct 161-220
31 Jul 161-220
30 Apr 161-220
31 Jan 160-220
31 Oct 150-220
31 Jul 150-220
31 Jul 140-310

Quality Earnings: SPLI.F is currently unprofitable.

Growing Profit Margin: SPLI.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SPLI.F is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.

Accelerating Growth: Unable to compare SPLI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPLI.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.9%).


Return on Equity

High ROE: SPLI.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies